CO2022007507A2 - Uso de reboxetina para tratar los trastornos del sistema nervioso - Google Patents
Uso de reboxetina para tratar los trastornos del sistema nerviosoInfo
- Publication number
- CO2022007507A2 CO2022007507A2 CONC2022/0007507A CO2022007507A CO2022007507A2 CO 2022007507 A2 CO2022007507 A2 CO 2022007507A2 CO 2022007507 A CO2022007507 A CO 2022007507A CO 2022007507 A2 CO2022007507 A2 CO 2022007507A2
- Authority
- CO
- Colombia
- Prior art keywords
- reboxetine
- nervous system
- treat disorders
- esreboxetine
- cataplexy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento se describen los métodos para el tratamiento de la narcolepsia con cataplexia, los cuales comprenden la administración de la reboxetina (la que incluye la esreboxetina) a un ser humano que lo necesite. La reboxetina (la que incluye la esreboxetina) también se puede utilizar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se dan a conocer en este documento los kits que comprenden una composición farmacéutica que comprende la reboxetina (la que incluye la esreboxetina) y las instrucciones para usar la composición farmacéutica para el tratamiento de la narcolepsia con cataplexia en un ser humano.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962943077P | 2019-12-03 | 2019-12-03 | |
US201962946295P | 2019-12-10 | 2019-12-10 | |
US16/740,329 US20200147093A1 (en) | 2018-10-15 | 2020-01-10 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,411 US20200147096A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,410 US20200147095A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,409 US11351175B2 (en) | 2018-10-15 | 2020-01-11 | Use of reboxetine to treat narcolepsy |
PCT/US2020/062560 WO2021113163A1 (en) | 2019-12-03 | 2020-11-30 | Use of reboxetine to treat nervous system disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022007507A2 true CO2022007507A2 (es) | 2022-06-21 |
Family
ID=81851750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0007507A CO2022007507A2 (es) | 2019-12-03 | 2022-05-31 | Uso de reboxetina para tratar los trastornos del sistema nervioso |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4069244A4 (es) |
JP (1) | JP2023504685A (es) |
KR (1) | KR20220108122A (es) |
CN (1) | CN114746097A (es) |
AU (1) | AU2020395082A1 (es) |
BR (1) | BR112022010677A2 (es) |
CA (1) | CA3163505A1 (es) |
CO (1) | CO2022007507A2 (es) |
CR (1) | CR20220247A (es) |
IL (1) | IL293536A (es) |
MX (1) | MX2022006630A (es) |
PE (1) | PE20230181A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL197985B1 (pl) * | 1999-07-01 | 2008-05-30 | Upjohn Co | Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku |
PT1459750E (pt) * | 1999-07-01 | 2005-08-31 | Pharmacia & Upjohn Co Llc | (s,s)- reboxetina para tratar a fibromialgia ou outras perturbacoes somatoformes |
CA2686723A1 (en) * | 2007-05-07 | 2008-11-13 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
TWI684450B (zh) * | 2013-03-13 | 2020-02-11 | 南韓商愛思開生物製藥股份有限公司 | 猝倒症之治療 |
-
2020
- 2020-11-30 CR CR20220247A patent/CR20220247A/es unknown
- 2020-11-30 AU AU2020395082A patent/AU2020395082A1/en not_active Abandoned
- 2020-11-30 BR BR112022010677A patent/BR112022010677A2/pt unknown
- 2020-11-30 EP EP20895126.9A patent/EP4069244A4/en active Pending
- 2020-11-30 CA CA3163505A patent/CA3163505A1/en active Pending
- 2020-11-30 IL IL293536A patent/IL293536A/en unknown
- 2020-11-30 CN CN202080083484.4A patent/CN114746097A/zh active Pending
- 2020-11-30 JP JP2022533248A patent/JP2023504685A/ja active Pending
- 2020-11-30 MX MX2022006630A patent/MX2022006630A/es unknown
- 2020-11-30 KR KR1020227022167A patent/KR20220108122A/ko unknown
- 2020-11-30 PE PE2022000980A patent/PE20230181A1/es unknown
-
2022
- 2022-05-31 CO CONC2022/0007507A patent/CO2022007507A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20230181A1 (es) | 2023-02-01 |
EP4069244A1 (en) | 2022-10-12 |
AU2020395082A1 (en) | 2022-06-09 |
CR20220247A (es) | 2022-08-18 |
EP4069244A4 (en) | 2023-12-20 |
CN114746097A (zh) | 2022-07-12 |
KR20220108122A (ko) | 2022-08-02 |
IL293536A (en) | 2022-08-01 |
JP2023504685A (ja) | 2023-02-06 |
BR112022010677A2 (pt) | 2022-08-16 |
MX2022006630A (es) | 2022-06-24 |
CA3163505A1 (en) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
CL2019000510A1 (es) | Adenovirus armado con un activador de células t biespecífico (bite). | |
CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
CO2019000938A2 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos | |
UY37271A (es) | Composiciones nasales de cannabinoides | |
CO2019000944A2 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
GT201700246A (es) | Métodos y kits para tratar la depresión | |
CO2019000945A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
CL2019000247A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
CL2019000246A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
CO2022014499A2 (es) | Moduladores de nlrp3 | |
CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
BR112019004540A2 (pt) | método para tratar demência em um paciente, composição farmacêutica, método para tratar demência em um paciente, método para reduzir a probabilidade de desenvolver demência em um paciente, composição para uso no tratamento de demência em um paciente, composição e composição para uso na redução da probabilidade de desenvolver demência em um paciente submetido a uma terapia longa de um fármaco não-esteroide anti-inflamatório ou aspirina | |
CO2022007507A2 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
CL2022001476A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
ECSP22092205A (es) | Composición farmacéutica acuosa de levilimab y su uso | |
AR122344A1 (es) | Uso de reboxetina para tratar desórdenes del sistema nervioso |